pubrio
Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

Public
alnylam.com
생명공학 연구2,600+ employeesFounded 2002🇺🇸 미국

SILENCE DISEASE. AMPLIFY LIFE.™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, five more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,600+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-24), Science Magazine (2018-25), Fast Company (Best Workplaces for Innovators 2020-25) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email [email protected] or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861 Fraudulent Recruitment Activity Be aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Alnylam Pharmaceuticals. Alnylam never conducts its interview process via messaging apps, freelance sites, or social media platforms. Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in "@alnylam.com."

설립
2002
직원
2,600+
산업
생명공학 연구
회사 유형
Public Company
주식
nasdaq: ALNY
본사
🇺🇸Cambridge, Massachusetts (+8)
전문 분야
연구제약생명 공학의료생명공학 연구
5 / 11
활성 시장
영국 · 독일 · 스위스
2
신규 시장
프랑스 · 인도
낮음
신뢰도
대부분 초기 시그널
0%
모멘텀
이전 기간 대비
33 / 100
확장 점수
성장 중
단계1탐색 중10투자 중
시그널 6건 · 최근 90일

글로벌 확장

실시간
영국독일스위스
단계
탐색 중투자 중진입 중운영 중
+8개 시장 더잠김
11개 중 3개 표시

시장 타임라인 및 시그널 피드 잠금 해제

활동 펄스

최근 90일간 시그널 6건.

최근 90일
채용
6↑ +100%
채용
마케팅 및 PR
0
활동 없음
제품 및 기술
0
활동 없음
+2개 카테고리 더잠김
5개 중 3개 표시

시장 진입 타임라인

이 회사가 각 시장에 진입한 순서 — 오래된 순부터 최신 순까지

1
🇬🇧영국1st 진입 시장 · 2022진전 중
투자 중
시그널 24건투자 중 단계
2
🇩🇪독일2nd 진입 시장 · 2024진전 중
투자 중
시그널 21건투자 중 단계
3
🇨🇭스위스3rd 진입 시장 · 2025진전 중
투자 중
시그널 11건투자 중 단계
+8개 시장 더잠김
11개 중 3개 표시
현재 단계투자 중자원 투입 중
신뢰도35%낮음
추적 시작2022첫 시그널

최근 시그널

채용🇮🇹 이탈리아2주 전

Sr Manager, Medical Science Liaison - LOMBARDIA EST / TRIVENETO

채용🇨🇭 스위스지난달

Director, Medical Affairs

가입하고 전체 시그널 피드를 확인하세요

알아두면 좋은 정보

Alnylam Pharmaceuticals 관련 자주 묻는 질문

Alnylam Pharmaceuticals의 사업, 시장, 성장 시그널에 대한 빠른 답변입니다.

SILENCE DISEASE. AMPLIFY LIFE.™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, five more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,600+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-24), Science Magazine (2018-25), Fast Company (Best Workplaces for Innovators 2020-25) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email [email protected] or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861 Fraudulent Recruitment Activity Be aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Alnylam Pharmaceuticals. Alnylam never conducts its interview process via messaging apps, freelance sites, or social media platforms. Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in "@alnylam.com."

오늘 바로 여정을 시작하세요

플랫폼부터 시작해도, 대화부터 시작해도 좋습니다

직접 Pubrio 를 사용하거나, 연구·리드 생성·데이터 통합을 저희 팀에 맡겨 보세요.

팀과 상담하기
Start Journey Image
pubrio

Pubrio는 50개 이상의 로컬 소스에서 비즈니스·인물·의도 데이터를 통합해 하나의 글로벌 그래프로 제공, 시장 전체 가시성을 확보하게 합니다.

© 2026 Pubrio. 모든 권리 보유.